The gut, creatine, and brain energy: what a 2026 depression trial actually showed

A Cell Metabolism paper connects a specific gut bacterium, a short-chain fatty acid, a creatine transporter, and depression — and tests the connection in a small human trial as an addition to standard antidepressant care.

Key takeaways

• A 2026 Cell Metabolism paper links depression to a specific microbial pathway: a deficit of Bifidobacterium pseudolongum → less bacterial acetate → downregulation of the creatine transporter SLC6A8 in the intestinal wall → reduced creatine absorption → energy deficit in brain regions involved in mood regulation.
• The mechanism was validated across human metabolomic profiling, mouse models of depression, and fecal microbiota transplant experiments.
• A 45-patient, 28-day randomized placebo-controlled trial found that adjunctive Bifidobacterium adolescentis plus creatine, added on top of existing antidepressant treatment, produced greater reductions in Hamilton Depression Rating Scale (HAM-D) scores than placebo added on top of the same standard care.
• The paper is one strong preliminary finding, not a treatment protocol. The senior author's stated next step is larger multicenter RCTs with a four-arm design (probiotic alone, creatine alone, combination, placebo) to determine whether the effect is real and clinically meaningful.

Depression is one of the most common chronic conditions in the world, and one of the most incompletely served by existing treatment. By some estimates, only about a third of patients with major depressive disorder achieve durable remission on first-line antidepressant therapy alone. That gap has fueled a growing research program, sometimes called metabolic psychiatry, that treats mood disorders less as isolated brain conditions and more as systemic energy-metabolism problems with downstream effects on brain function.

A February 2026 paper in Cell Metabolism from the Cao lab is one of the more mechanistically detailed entries in that program to date ^[1]. It identifies a specific bacterial deficit in patients with depression, traces the deficit through a specific short-chain fatty acid, a specific intestinal transporter, and a specific brain energy substrate. It then tests, in a small randomized trial, whether restoring the pathway alongside standard care improves depression symptoms.

The paradigm the paper sits inside

Before walking through the paper, the broader frame is worth naming. Depression is characterized in imaging studies by measurable metabolic deficits in specific brain regions where neurons appear to have insufficient energy substrate to function normally. The clinical fields sometimes described under labels like metabolic psychiatry treat this observation seriously: if the brain in depression is energy-starved in specific circuits, then interventions that shift metabolism may have effects on mood in addition to their better-known effects on other systems.

This does not replace the psychological and social dimensions of mental health. It sits alongside them. What the Cao paper contributes is a specific mechanism connecting the gut microbiome to the energy currency the brain needs, and a specific place to intervene.

What the paper found

The researchers began with deep metabolomic profiling in cerebrospinal fluid, blood, and stool from 15 patients with major depressive disorder and 16 matched controls ^[1]. One molecule stood out with an unusual pattern: creatine.

Creatine is a small molecule that shuttles high-energy phosphate groups within cells, functioning as one of the primary short-term energy buffers in tissues with high and variable energy demand. In the depressed patients, creatine levels were lower in blood and cerebrospinal fluid but higher in stool. In the authors' framing, "unique opposing trends across biological compartments suggest a peripheral and cerebral creatine imbalance in depression pathophysiology." The plain-language version: the creatine was there in the gut but was not being absorbed properly, so less of it reached the brain.

The researchers then moved to mouse models of depression and found the same pattern. Creatine was lower in blood, cerebrospinal fluid, and depression-relevant brain regions such as the medial prefrontal cortex, and the drops in creatine tracked with more depression-like behavior.

To test whether the microbiome was causally involved, they performed fecal microbiota transplants from depressed patients into mice. The recipient mice developed lower systemic creatine and more depression-like behavior; evidence that something transferable in the microbiome was mediating the metabolic phenotype.

The mechanism: acetate, SLC6A8, and creatine absorption

The next question was which bacteria were doing the work. Comparing microbiome composition between depressed patients and controls, the researchers identified Bifidobacterium pseudolongum as one of the most consistently reduced species in depression ^[1].

B. pseudolongum and related Bifidobacterium species produce acetate as one of their primary metabolic byproducts. Acetate is a short-chain fatty acid, part of the same family (butyrate, propionate, acetate) that gut bacteria produce when they ferment fiber and that has long been recognized as a signaling currency between the gut and the rest of the body.

The paper's core mechanistic contribution is showing what acetate does specifically in this context. Bacterial acetate promotes the expression of SLC6A8, the creatine transporter, in intestinal epithelial cells. The mechanism runs through histoneacetylation. Acetate contributes acetyl groups that modify histones around the SLC6A8 gene, increasing its expression and, downstream, the intestinal cell's capacity to absorb creatine.

The chain the paper validated:

Depleted B. pseudolongum → less bacterial acetate → less histone acetylation at Slc6a8 → less creatine transporter expression → less intestinal creatine absorption → less systemic and brain creatine → energy deficit in mood-relevant brain regions.

Knocking out Slc6a8 in mouse intestinal cells reduced systemic creatine and produced depression-relevant electrophysiological changes in the medial prefrontal cortex. Restoring the pathway restored the phenotype.

The clinical trial

Having built the mechanism, the researchers tested whether it could be therapeutically leveraged in humans. They ran two clinical studies.

The first, in healthy participants, tested whether combining a Bifidobacterium probiotic with creatine supplementation enhanced creatine absorption. The strain used was Bifidobacterium adolescentis, chosen for practical availability. It is a well-characterized food-grade Bifidobacterium species that also produces acetate through the same pathway as B. pseudolongum. The combination, at 2 × 10⁸ CFU/day of B. adolescentis and 3 g/day of creatine monohydrate, increased creatine absorption relative to creatine alone.

The second study is the one that has drawn the most attention. Forty-five patients with major depressive disorder who all had already receiving standard antidepressant medication. The patients were randomized to receive either B. adolescentis plus creatine or matched placebo, in addition to their ongoing treatment. After 28 days, the intervention group showed significantly greater reductions in HAM-D depression scores than the placebo group ^[1].

This is a real signal, and it is a small one. Forty-five patients is a proof-of-concept sample. Twenty-eight days is a short window relative to the natural course of depression. The comparison is against placebo added to antidepressant therapy meaning the paper is reporting that the combination may add value on top of standard care, not that it replaces or outperforms it. The senior author has explicitly stated that the next step is a larger, four-arm, multicenter trial (probiotic alone, creatine alone, combination, placebo) to establish whether the combination genuinely adds meaningful benefit and to disentangle which component is doing the work.

What this means, and what it does not

A paper this mechanistically clean is easy to overread. Two guardrails are worth holding.

This is one preliminary trial, added to a strong mechanistic story. The combination of metabolomic profiling, causal mouse experiments, FMT validation, and a randomized placebo-controlled human trial is a serious body of evidence for a paper of this age. It is not a body of evidence sufficient to justify treating the intervention as an established therapy. Larger trials are needed and are planned.

The trial was adjunctive, not standalone. The participants remained on their prescribed antidepressant medication throughout. The paper does not license a "skip your medication and take creatine and a probiotic" reading. That would be both scientifically unsupported and, for many patients, medically dangerous. If the intervention works, it works as an addition to standard care.

The broader significance of the paper is different from its trial results. It suggests that the observation that the field has been circling for a decade (that depression may be, at least in part, a disorder of brain energy metabolism) has a specific, tractable node in the gut microbiome. It also suggests that the "gut-brain axis" is not one thing but many, and that individual axes can be identified, mapped, and eventually intervened on with useful specificity. That is what a good mechanism paper does. It replaces a vague picture with a specific one.

Where this fits in a life

Practical implications, honestly stated:

• This is not a self-directed protocol. If you are being treated for depression, changes to your regimen, including the addition of supplements, should be made in coordination with the prescriber who knows your full clinical picture. Some supplements interact with psychiatric medications in non-obvious ways.
• The mechanism does support the broader gut-and-mood story. Fiber-forward eating, fermented foods, and adequate sleep are the reliably supportive habits that shape the microbiome in the direction the paper's biology implicates. None of these currently treat depression on its own, and none of them is a substitute for evidence-based mental health care.
• The metabolic psychiatry paradigm is worth knowing exists. Clinics at Stanford, Harvard, and elsewhere now offer metabolic-psychiatry consultations for patients whose depression has not responded adequately to standard care. If that describes your situation, the paradigm is worth raising with a mental health provider.

If you or someone you love is experiencing depression, please reach out to a mental health professional. In the United States, you can call or text 988 to reach the Suicide and Crisis Lifeline any time.